ENDRA Life Sciences (NDRA) Free Cash Flow (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Free Cash Flow for 11 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 14.56% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$5.0 million (up 23.59% YoY), while the FY2025 annual figure was -$5.2 million, up 29.89% from the prior year.
• Free Cash Flow improved to -$1.1 million in Q1 2026 per NDRA's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$1.1 million in Q2 2025 and bottomed at -$3.4 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$2.1 million across 5 years, with a median of -$2.2 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow decreased 21.27% — and 2025, when it surged 46.26%.
• ENDRA Life Sciences' Free Cash Flow stood at -$3.1 million in 2022, then surged by 30.24% to -$2.2 million in 2023, then surged by 30.52% to -$1.5 million in 2024, then decreased by 6.33% to -$1.6 million in 2025, then surged by 30.53% to -$1.1 million in 2026.
• Business Quant data shows NDRA's Free Cash Flow at -$1.1 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.2 million in Q3 2025.